Digital twins are being tested to improve existing factory capacity. Artificial intelligence (AI) in pharmaceutical manufacturing remains largely in the pilot stage, even as drugmakers test it for production and quality monitoring amidst rising demand for obesity and diabetes treatments. A GlobalData report said companies face challenges from outdated systems, uneven data quality, and the difficulty of applying AI in regulated manufacturing environments. Success will depend on execution and the